Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Pediatric Rheumatology
How do you approach the management of autoimmune lymphoproliferative syndrome complicated by HLH?
Related Questions
How do you treat MAS in patients with systemic JIA or AOSD with HLA-DRB1*15 alleles given risk for DRESS hypersensitivity to IL1 or IL6 inhibitor therapy?
Do you always pursue testing for NOD2 mutations when you are suspecting a diagnosis of Blau syndrome?
Do you routinely pursue cardiac evaluation in children presenting with post-streptococcal reactive arthritis given the diagnostic overlap with acute rheumatic fever?
How would you approach a patient with SLE and class II LN who has persistent lupus activity and incomplete B-cell depletion on rituximab therapy?
In a young patient who was vaccinated to chickenpox as a child (no previous varicella infection) should the patient receive a shingles vaccine prior to starting Rinvoq?
Would you consider combination belimumab and anakinra for a patient who has SLE and MAS?
When using IV TNF inhibitors, do you follow levels to determine if the current dose is adequately treating the patient?
In a patient with SJIA who has been stable on Anakinra however is now planning to conceive or becomes pregnant, would you consider switching to Cimzia?
How would you approach a patient with the diagnosis of Yao Syndrome with manifestations including dermatitis, arthralgia, severe keratoconjunctivitis sicca, and gastroparesis who has failed to respond to dupilumab and canakinumab?
How would you approach management of a patient with sJIA that was previously well controlled on tocilizumab but is now having ongoing joint disease activity?
